HPN Prevalence (US)
10–20K
Approximately 10,000–20,000 Americans depend on home parenteral nutrition (HPN) for survival due to intestinal failure.[1]
What Is It
Definition, mechanism, and the clinical reality of end-stage GI failure and short bowel syndrome at end of life. What the hospice team needs to understand on day one.
SBS Incidence
3–4/M
Annual incidence of short bowel syndrome (SBS) in the US is approximately 3–4 per million population.[2]
TPN Withdrawal Survival
2–6 wk
Patients with no residual absorptive GI function who withdraw TPN typically survive 2–6 weeks from dehydration and electrolyte failure.[7]
MBO Median Survival
1–6 wk
Malignant bowel obstruction without surgical option: median survival 1–6 weeks with conservative management.[18]
Intestinal failure is defined as the reduction of gut function below the minimum necessary for the absorption of macronutrients, water, and electrolytes such that intravenous supplementation is required to maintain health. The patient who arrives at hospice with end-stage GI failure has a bowel that cannot sustain life. They have been kept alive by total parenteral nutrition (TPN) — a compounded IV solution infused through a central venous catheter, typically over 8–14 hours nightly — and that TPN is the functional equivalent of a ventilator. Without it, they will die. The decision to withdraw TPN carries the same clinical, ethical, and emotional weight as the decision to withdraw mechanical ventilation.[7][8]
Short bowel syndrome (SBS) — the most common cause of chronic (Type 3) intestinal failure requiring long-term parenteral nutrition — results from surgical resection of more than 70% of the small intestine or from a remnant bowel length below approximately 100–150 cm with preserved colon (or below 200 cm without colon). The causes that bring patients to this point are multiple: Crohn's disease with multiple resections (the most common cause in developed countries), mesenteric ischemia with massive bowel infarction, radiation enteritis from pelvic or abdominal radiation, malignant bowel obstruction (inoperable obstruction from cancer or carcinomatosis), and GI dysmotility from systemic sclerosis or chronic intestinal pseudo-obstruction.[1][3]
The patient who requires home TPN has organized their entire life around an infusion pump that runs every night. They know the weight of their supply box. They know which arm has a good vein and which does not. They have been to the emergency department for central line infections too many times to count. And many have been eating almost nothing for years — watching their family eat at the holiday table while they sit beside food they cannot absorb. The hospice clinician who walks in to discuss TPN withdrawal walks into a conversation of the same weight as ventilator withdrawal.[8]
🧭 Clinical framing
TPN in intestinal failure is not a medication — it is a life-sustaining treatment. The ethics of withholding and withdrawing life-sustaining treatment apply to TPN with the same force as they apply to ventilators and vasopressors. Unlike the ventilator patient who is typically unconscious, the TPN-dependent patient is typically awake, cognitively intact, and capable of full participation in the withdrawal decision — the same dynamic as dialysis withdrawal in ESRD.
"The TPN patient is unique in hospice. They are not dying from a tumor you can see on a scan or a heart that is failing on an echo. They are dying because a machine that has kept them alive for years is being turned off — and they are sitting there watching you do it. Every skill you have in ventilator withdrawal applies here, except the patient is looking you in the eye."
— Waldo, NP · Terminal2
How It's Diagnosed
GI failure assessment and clinical staging the hospice clinician must understand from prior records. Most patients arrive with an established diagnosis — this section helps you read the chart.
Intestinal Failure Classification (ESPEN)
Guideline- Type 1 — Acute, self-limiting: Post-operative ileus, acute mesenteric ischemia resolving with revascularization. Days to weeks. Resolves with supportive care.
- Type 2 — Prolonged acute: Complex post-surgical complications, enterocutaneous fistulae, sepsis with GI failure. Weeks to months. Requires multidisciplinary care and PN.
- Type 3 — Chronic: Long-term HPN-dependent intestinal failure — SBS from Crohn's, radiation enteritis, chronic pseudo-obstruction. Years. The hospice patient is almost exclusively Type 3.[1]
Remnant Bowel Anatomy — Critical Data
- Residual small bowel length: From operative reports — the single most important prognostic variable. Below 100–150 cm with colon or 200 cm without colon = TPN-dependent.[2]
- Colon in continuity? The colon salvages water, electrolytes, and short-chain fatty acids. Patients with preserved colon absorb significantly more than those without.
- Anastomosis or ostomy site: Jejunostomy = rapid transit, high output (1.5–3 L/day). Ileostomy = moderate. Colostomy = slowest transit.
- High-output stoma: Output >1.5 L/day = high-output condition causing dehydration and electrolyte depletion even with TPN.[35]
Central Venous Access Assessment
- Remaining access sites: How many usable central venous access sites remain? Document bilateral subclavian, internal jugular, and femoral veins. Each thrombosed vein is one fewer option.[30]
- Catheter type: Tunneled catheter (Hickman/Broviac) vs. implanted port vs. PICC. Tunneled catheters are standard for long-term HPN.
- CRBSI history: Number of catheter-related bloodstream infections (CRBSIs) in the past year. ≥2 per year is a hospice eligibility criterion.[29]
- Access exhaustion protocol: If all standard sites are thrombosed, translumbar or transhepatic access via interventional radiology may have been attempted — document this.[31]
TPN-Associated Liver Disease (TPNALD)
- Liver enzymes: Progressive elevation of alkaline phosphatase, GGT, and bilirubin indicates TPNALD progression from steatosis → steatohepatitis → fibrosis → cirrhosis.[26]
- MELD score: MELD ≥17 in a TPN-dependent patient indicates significant liver disease and is a hospice eligibility criterion.[27]
- Lipid emulsion type: Omega-6-predominant soybean oil emulsions (Intralipid) are hepatotoxic with long-term use. Fish-oil-based emulsions (Omegaven, SMOFlipid) are hepatoprotective.[28]
- Imaging: Ultrasound or CT showing hepatomegaly, steatosis, or cirrhotic changes. Document portal hypertension signs if present.
💡 Hospice Eligibility Framework for GI Failure
TPN dependence PLUS one or more of: recurrent CRBSI (≥2 per year), exhausted central venous access, TPNALD progressing to cirrhosis (MELD >17), weight loss >10% despite TPN, functional decline below 50% PPS, or underlying malignancy with poor prognosis. Malignant bowel obstruction: inoperable MBO confirmed by imaging in advanced/recurrent malignancy with no further surgical or stenting option and a decision to pursue comfort-directed management.[7]
Causes & Risk Factors
The specific disease entities that produce end-stage GI failure and the clinical dimensions relevant to end-of-life care.
Crohn's Disease with Surgical Short Bowel
The most common cause of SBS and Type 3 intestinal failure in the developed world. The Crohn's patient at hospice enrollment has had the disease for 20–40 years, multiple surgeries, and has reached the point where further surgical options are exhausted and the nutritional deficit cannot be overcome by gut rehabilitation.[4]
- Each bowel resection removes absorptive surface area that cannot regenerate
- The patient was told at diagnosis that Crohn's was "manageable" — reaching TPN dependence represents failure of every available medical and surgical option
- The specific grief: they have watched IBD management advance significantly while their own disease advanced further
Radiation Enteritis
The most severe and most refractory GI mucosal failure in all of gastroenterology. Late complication of pelvic and abdominal radiation that destroys intestinal mucosal architecture through obliterative endarteritis, submucosal fibrosis, and enteric nervous system damage.[5][50]
- Radiation dose that cured the cervical or rectal cancer destroyed the small bowel over years
- Produces: mucosal necrosis, fistulae (rectovaginal, enterocutaneous, enterovesical), strictures, dysmotility
- The bowel appears anatomically intact but cannot perform absorptive or barrier functions
Mesenteric Ischemia / Massive Bowel Infarction
The most acute cause of intestinal failure — massive small bowel necrosis from superior mesenteric artery occlusion or mesenteric venous thrombosis. Survivors of the initial event who undergo massive resection become immediately and irreversibly TPN-dependent.[6]
- Acute onset — patient goes from normal GI function to total intestinal failure in hours
- Often occurs in elderly patients with atherosclerotic disease or hypercoagulable states
- The adaptation to TPN dependence is sudden, unlike the gradual progression of Crohn's
Systemic Sclerosis (Scleroderma) GI Dysmotility
SSc destroys GI motility from esophagus to rectum through progressive smooth muscle fibrosis and enteric nervous system degeneration. Chronic intestinal pseudo-obstruction (CIPO) produces functional bowel failure without anatomical obstruction.[46]
- The bowel is present but non-functional — peristalsis has ceased or is ineffective
- Bacterial overgrowth in stagnant bowel further impairs absorption
- SSc patients may also have esophageal dysmotility, making oral intake impossible
Malignant Bowel Obstruction (MBO)
Inoperable bowel obstruction from peritoneal carcinomatosis or direct tumor invasion — most commonly from ovarian, colorectal, and gastric cancers. MBO represents irreversible mechanical obstruction without surgical option.[18]
- Differs from SBS: the bowel is present but obstructed, not absent
- The symptom management triad — octreotide, glycopyrrolate, haloperidol — is the cornerstone of comfort care
- Timeline is typically weeks, not months or years
Chronic Intestinal Pseudo-Obstruction (CIPO)
Primary or secondary motility failure producing functional obstruction without mechanical cause. May be neuropathic (enteric nervous system degeneration) or myopathic (smooth muscle disease).[47]
- Episodes of pseudo-obstruction mimic mechanical obstruction — abdominal distension, vomiting, pain
- Often complicates SSc, amyloidosis, paraneoplastic syndromes, or mitochondrial disease
- TPN dependence develops when oral intake cannot sustain nutrition through the dysmotile bowel
❤️ For families: "Why did this happen?"
Your person's intestine stopped working — either because too much was removed by surgery, because radiation treatment damaged it, because blood supply was lost, or because a disease stopped it from moving food through. This was not caused by something they ate or didn't eat. It was not caused by something they did wrong. It is the result of a medical condition that, despite the best available treatment, progressed to the point where the intestine can no longer do its job. The TPN — the nightly infusion — has been doing the job the intestine can no longer do.
Treatments & Procedures
TPN decision-making at hospice enrollment — the most ethically and emotionally significant clinical decision in GI failure hospice care.
TPN in intestinal failure is not a medication — it is a life-sustaining treatment equivalent to mechanical ventilation in respiratory failure. The ethics of withholding and withdrawing life-sustaining treatment apply to TPN with the same force as they apply to ventilators and vasopressors. The patient who cannot absorb nutrition orally or enterally will die without TPN — this is a clinical fact, not a clinical opinion. The TPN withdrawal decision therefore carries the weight of the ventilator withdrawal decision in ICU palliative care.[7][8]
TPN Continuation at Hospice Enrollment
GuidelineContinuing TPN in hospice is appropriate and hospice-compatible when:
- TPN provides meaningful comfort benefit — prevents symptomatic malnutrition, maintains energy and function
- Central access is functional — no active CRBSI, line is patent and secure
- Patient wants to continue — the decision to continue is as autonomous as the decision to stop
- TPN maintains quality of life rather than simply extending the dying process
- Document the comfort-benefit rationale explicitly in the care plan[9]
TPN Withdrawal Decision Framework
Grade AThe clinical framework for TPN withdrawal assessment:
- Does TPN provide comfort benefit? In late-stage IF with TPNALD cirrhosis, fluid overload, or exhausted access, TPN may cause direct harm
- Does TPN prolong a dying process the patient would prefer shorter? The terminal cancer patient on TPN for MBO may be prolonging active dying
- Is TPN consistent with the patient's values and goals? The patient defines "acceptable quality of life," not the clinician
- ESPEN position: TPN withdrawal in terminal illness is ethically appropriate when burden exceeds benefit[7]
Venting PEG for MBO
- Indication: Inoperable MBO with high-level proximal obstruction and significant nausea/vomiting despite pharmacological triad[19]
- Mechanism: Decompresses the stomach — reduces vomiting by draining gastric contents through the PEG rather than through vomiting
- Advantage over NGT: More comfortable, socially acceptable, allows oral intake for taste/pleasure (it drains out rather than being absorbed)
- Hospice-compatible: A comfort intervention that dramatically reduces symptom burden
Gut Rehabilitation & Transplantation
- Teduglutide (GLP-2 analog): Promotes intestinal adaptation in SBS — may reduce TPN volume requirements. Typically attempted before hospice enrollment.[42]
- Intestinal transplantation: Combined bowel and liver transplant for intestinal failure with TPNALD. 5-year survival ~50%. Most hospice patients have been evaluated and found not to be candidates.[44]
- At hospice enrollment: These options have typically been exhausted or declined. Document prior rehabilitation attempts and transplant evaluation status.
🚨 The TPN Withdrawal Conversation Must Happen at Enrollment
Even if withdrawal is not the immediate plan, the patient who is asked about their wishes regarding TPN at hospice enrollment has a documented set of preferences before the decision is forced by a clinical event — CRBSI, hepatic decompensation, or access failure. Ask directly: "If there comes a time when the line is infected and we cannot get another one, or if the liver disease gets worse, what would you want to do about the TPN?" Document whatever the patient says. This is the most important advance directive question for this population.
When Therapy Makes Sense
Evidence-based criteria for continuing TPN, MBO pharmacological management, and other interventions at hospice enrollment.
TPN continuation and MBO symptom management at hospice enrollment are not curative interventions — they are comfort interventions when applied correctly. The clinical question is not "should we treat?" but "does this specific intervention provide comfort benefit to this specific patient at this point in their trajectory?"[7]
- 01TPN continuation when it provides comfort benefit: TPN that prevents symptomatic malnutrition, maintains energy and functional capacity, and is consistent with the patient's goals is a hospice-compatible comfort intervention. Document the comfort-benefit rationale at every recertification.[9]
- 02MBO pharmacological triad at enrollment: Octreotide + glycopyrrolate (or hyoscine/scopolamine) + haloperidol in a CSCI — start all three simultaneously at enrollment for any patient with MBO. These three medications together manage MBO symptoms more effectively than any single agent.[15]
- 03Venting PEG discussion at enrollment: For any MBO patient with high-level proximal obstruction and significant nausea/vomiting — the venting PEG is a comfort intervention that dramatically reduces symptom burden. Discuss it before the patient is too debilitated for the procedure.[19]
- 04Loperamide for high-output stoma management: The highest-priority comfort medication in high-output SBS. Doses in SBS are much higher than standard antidiarrheal doses — up to 16–24 mg/day in divided doses 30 minutes before meals.[36]
- 05Oral rehydration solution as a formal prescription: St. Mark's ORS (sodium 90–120 mmol/L) or WHO ORS — prescribed specifically, not generically. The SBS patient who drinks plain water or hypotonic fluids loses more sodium than they gain.[35]
- 06Subcutaneous hydration (hypodermoclysis): For comfort dehydration management after TPN withdrawal — 500–1000 mL of normal saline via butterfly needle in subcutaneous tissue. The comfort hydration that does not require central venous access.[39]
- 07CRBSI prevention protocol at enrollment: Aseptic line care technique, ethanol lock therapy for recurrent CRBSI, chlorhexidine-impregnated dressings. Document the CRBSI management protocol — treat, salvage, replace, or use CRBSI as the natural transition to TPN withdrawal.[29]
When It Doesn't
Knowing when treatment stops helping is the most important clinical skill in GI failure hospice care.
The TPN that was appropriate two months ago may not be appropriate today. The decision to stop TPN in the dying phase is not a new decision — it is the implementation of the advance directive documented at enrollment. Reassess TPN at every hospice visit against the comfort-benefit standard.[7][8]
- 01TPN continuation in the actively dying patient (PPS <20%): TPN that maintains biochemical stability in a patient who is unconscious, actively dying, and receiving no comfort benefit from the nutritional support is not a comfort intervention. TPN in the final days may increase fluid retention, secretions, and edema without providing any subjective benefit.[9]
- 02Forcing oral intake in a patient with MBO: Offering food to a patient with complete bowel obstruction increases gastric secretion load and worsens vomiting and nausea. The compassionate response to "I'm hungry" in MBO is ice chips, oral care, and small tastes for pleasure — not food. The family must understand this and why.[18]
- 03NGT as long-term MBO management: NGTs are appropriate for acute decompression but not for long-term comfort management — nasal irritation, discomfort, and social isolation of nasopharyngeal intubation in a dying patient. The venting PEG is the appropriate long-term decompression strategy.[19]
- 04Ondansetron alone for MBO nausea: Ondansetron (5-HT3 antagonist) is the most commonly prescribed antiemetic in hospice but is less effective for MBO nausea than haloperidol — the mechanism of MBO nausea is not primarily serotonergic. Starting with ondansetron alone for MBO and not including haloperidol is treating the wrong mechanism.[22]
- 05High-flow IV hydration in MBO with ascites or third-spacing: Aggressive IV hydration in a patient with peritoneal carcinomatosis worsens ascites, increases intraluminal secretion volume above the obstruction, and increases vomiting. Use subcutaneous hydration at comfort volumes (500–1000 mL/day) instead of aggressive IV resuscitation.[39]
- 06Metoclopramide in complete bowel obstruction: Prokinetic agents are contraindicated in confirmed complete mechanical obstruction — increasing peristalsis against a fixed obstruction increases colic and can cause perforation. Metoclopramide is only appropriate in partial obstruction or functional ileus.[18]
📋 Clinician note
The most common clinical error in GI failure hospice care is treating TPN as a default rather than reassessing it as a comfort intervention at every visit. Ask at every visit: "How has the TPN been this week? Is it helping you feel better or is it adding to the burden?" The answer may change as the disease progresses. Document the reassessment.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical; D = expert opinion.
MBO Pharmacological Triad — Octreotide + Glycopyrrolate + Haloperidol
Grade AOctreotide 300–600 mcg/24h CSCI + Glycopyrrolate 0.6–1.2 mg/24h CSCI + Haloperidol 5–15 mg/24h CSCI
The combination addresses the three primary symptom mechanisms of MBO simultaneously: octreotide reduces secretion volume (the fluid load above the obstruction that produces vomiting); glycopyrrolate/hyoscine reduces intestinal spasm (colicky pain of peristalsis against obstruction); haloperidol reduces central nausea from CTZ stimulation. Ripamonti et al. RCT confirmed octreotide superiority over hyoscine alone for nasogastric output reduction. The three-drug CSCI through a single syringe driver allows continuous symptom management.[15][16][22]
TPN Withdrawal — Planned Clinical Event with Comfort Protocol
Grade APre-withdrawal: establish SC hydration + comfort medications + family preparation. Withdrawal day: stop TPN, begin hypodermoclysis 500–1000 mL/24h
TPN withdrawal in intestinal failure is ethically and clinically equivalent to the ventilator withdrawal sequence. ESPEN position statement: withdrawal of artificial nutrition in terminal illness is ethically appropriate when burden exceeds benefit. The protocol: pre-withdrawal comfort planning (subcutaneous hydration, antiemetics, anxiolytics, opioids for any pain), family meeting documenting understanding and consent, planned withdrawal at a time when clinical support is available, not at 2 AM during a CRBSI crisis.[7][8][10]
Dexamethasone Trial for Partial MBO
Grade BDexamethasone 6–16 mg IV/SQ daily for 5–7 days, then taper if no response
Corticosteroids reduce peritumoral edema and may partially relieve malignant bowel obstruction in 30–40% of patients. Feuer and Broadley Cochrane review found a trend toward resolution of obstruction with corticosteroids. Time-limited trial: if no improvement in 5–7 days, discontinue. Monitor for steroid side effects — hyperglycemia, agitation, insomnia, oral candidiasis.[20]
Venting PEG for Inoperable MBO
Grade BEndoscopic or interventional radiology-guided PEG placement; drain opened after meals or continuously as needed
Venting gastrostomy provides mechanical decompression that complements pharmacological management. Systematic review (Davis et al.) reports symptom relief in 85–90% of patients with MBO. More comfortable and socially acceptable than NGT. Allows oral intake for taste and pleasure — food and liquid drain through the PEG rather than causing vomiting. Consider for any MBO patient who does not achieve adequate symptom control with the pharmacological triad alone.[19]
Subcutaneous Hydration (Hypodermoclysis) Post-TPN
Grade BNS or Ringer's lactate 500–1500 mL/24h via 25-gauge butterfly needle SC in abdomen or anterior thigh
Bruera et al. systematic review: subcutaneous hydration is safe, effective, and well-tolerated in palliative care. Provides comfort hydration without requiring central venous access. Prevents the most uncomfortable features of dehydration (dry mouth, confusion, myoclonus) while avoiding the fluid overload of aggressive IV hydration. The ideal post-TPN hydration strategy for patients who have withdrawn central venous nutrition.[39][40]
Ethanol Lock Therapy for Recurrent CRBSI
Grade C70% ethanol instilled into catheter lumen for 2–24 hours between TPN infusions
Reduces CRBSI recurrence in HPN patients by disrupting biofilm in the catheter lumen. May extend catheter life and delay access exhaustion. Compatible with hospice management when CRBSI prevention is a priority for maintaining TPN. Not all catheter materials are compatible — confirm catheter type before instilling ethanol.[29]
Teduglutide for SBS — Pre-Hospice Intervention
Grade ATeduglutide 0.05 mg/kg SQ daily (STEPS trial regimen)
Jeppesen et al. NEJM 2012 (STEPS trial): teduglutide significantly reduced TPN volume requirements in SBS. GLP-2 analog that promotes intestinal adaptation — mucosal growth, villus height increase, improved absorption. Typically attempted before hospice enrollment. At hospice, document whether it was tried and the outcome. Not appropriate to initiate at hospice enrollment.[42]
Comfort Feeding in GI Failure
Grade DSmall tastes for pleasure; ice chips; oral care with moistened swabs; flavor experiences without nutritional intent
For patients with partial absorptive function or with MBO managed by venting PEG: carefully offered small amounts of food for the social, sensory, and emotional experience of eating — not for nutrition. The patient with a venting PEG can taste and enjoy food knowing it will drain through the PEG. Risk-benefit must be individualized: some patients accept the discomfort of small intake for the profound emotional benefit of participating in a shared meal.[49]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to GI failure. The most constrained supplement safety landscape in hospice.
⚠️ Critical Safety Context for GI Failure
End-stage GI failure and MBO create the most constrained supplement safety landscape in hospice. In intestinal failure and malabsorption, oral supplements may not be absorbed at all, may be absorbed erratically, or may increase GI secretion load and worsen symptoms. The TPN-dependent patient who takes oral supplements is providing substrate for bacterial overgrowth, increasing ostomy output, and potentially worsening symptoms. The MBO patient who takes anything by mouth increases gastric secretion load. The fundamental principle: what can be absorbed, and does it reach systemic circulation? For most oral supplements in severe intestinal failure, the answer is no.
"The conversation about supplements in GI failure is different from every other diagnosis. The patient who has been on TPN for six years knows more about nutrition than most clinicians. The right conversation is not 'which supplements should you take?' — it's 'the only reliable supplementation route for you is through the TPN itself, and here's how we make sure it includes everything you need.'"
— Waldo, NP
| Supplement / Route | Evidence | Dose / Protocol | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| IV Multivitamins in TPN | Grade A | Standard adult MVI added to TPN daily (MVI-13 or equivalent) | The only reliable micronutrient supplementation route in TPN-dependent patients — prevents deficiency syndromes | Confirm TPN prescription includes all required vitamins and trace elements; adjust vitamin K based on anticoagulation status[33] |
| IV Trace Elements in TPN | Grade A | Zinc 3–5 mg, selenium 40–60 mcg, copper, chromium, manganese — added to TPN | Prevents zinc deficiency (impaired wound healing, dermatitis), selenium deficiency (cardiomyopathy), copper deficiency (anemia) | Reduce manganese if liver disease present (hepatic accumulation); monitor copper in cholestasis[33] |
| Ginger (limited SBS patients with residual function) | Grade C | 250 mg PO QID if tolerated and absorptive function adequate | Antiemetic properties — may reduce nausea in patients with some residual GI function who are not completely TPN-dependent | Increases GI secretions — contraindicated in high-output stoma or MBO; may increase bleeding risk with anticoagulants[33] |
| Peppermint oil (topical/aromatherapy only) | Grade C | Aromatherapy inhalation or topical to temples for nausea | Non-oral antiemetic adjunct — bypasses GI absorption entirely; small studies suggest benefit for chemotherapy-related nausea | Do not administer orally in intestinal failure; menthol may cause esophageal relaxation in SSc patients with GERD |
| Probiotics | Grade D | NOT RECOMMENDED in GI failure | Theoretical benefit for bacterial overgrowth in SBS — but unproven and potentially dangerous in this population | ⚠ AVOID: risk of translocation and bacteremia through compromised intestinal barrier; case reports of Lactobacillus bacteremia in SBS patients with central lines |
| Glutamine (oral) | Grade C | 30 g/day PO in divided doses (if absorptive function present) | May enhance intestinal adaptation in SBS — enterocyte fuel source; mixed evidence from growth hormone + glutamine trials | Requires residual absorptive function to be effective; not absorbed in complete intestinal failure; hepatotoxic at high doses in liver disease[45] |
🚫 Avoid in GI Failure / MBO
- Any oral supplement in complete MBO: Nothing taken orally is absorbed in complete bowel obstruction — it increases gastric secretion load and worsens vomiting
- Probiotics in intestinal failure: Risk of translocation and bacteremia through compromised intestinal barrier and central venous access — case reports of fatal probiotic-related sepsis in TPN-dependent patients
- High-fiber supplements (psyllium, inulin): Increase stoma output in SBS; may worsen obstruction symptoms in MBO; increase bacterial fermentation and gas in dysmotile bowel
- St. John's Wort: Potent CYP3A4 inducer — reduces efficacy of multiple medications including opioids, anticoagulants, and immunosuppressants; erratic absorption in GI failure makes drug interactions unpredictable
- Turmeric/curcumin at high doses: Antiplatelet effects; hepatotoxic in high doses especially with existing TPNALD; unreliable absorption in intestinal failure
Timeline Guide
Two distinct trajectories: the chronic TPN-dependent intestinal failure timeline (years on HPN) and the acute MBO timeline (days to weeks). Both converge at the hospice doorstep.
The GI failure end-stage timeline has two distinct patterns. The chronic TPN-dependent patient has been on home parenteral nutrition for years — punctuated by CRBSI events, progressive access exhaustion, and liver disease accumulation — eventually reaching the hospice-eligibility threshold. The acute MBO patient moves from obstruction to death in days to weeks. This timeline addresses both.[1][18]
YRS
Chronic TPN-Dependent Trajectory — Years on Home PN
- The diagnosis that started the intestinal failure — the Crohn's surgery, the mesenteric ischemia event, the radiation that was supposed to cure the cancer
- First TPN infusion and adaptation to nightly infusion — learning to program the pump, manage the line, organize the supply deliveries
- First CRBSI and the antibiotic treatment, line salvage or replacement — the first of many
- Years of HPN management: weekly dressing changes, monthly labs, pharmacy deliveries, the pump alarm at 3 AM
- TPNALD appearing on labs — progressive liver enzyme elevation, ultrasound changes
- Gut rehabilitation attempt that did not produce TPN independence
- The hospice clinician who asks "tell me about the years of living on TPN" receives context that no lab value can provide
MOS
Hospice Eligibility / Transition Phase
- CRBSI frequency increasing — 2+ per year; each infection is harder to treat, more access sites thrombosed
- MELD score rising above 17 — TPNALD progressing toward cirrhosis; jaundice may appear
- Central venous access sites exhausting — bilateral subclavian thrombosis, last IJ catheter
- Weight loss >10% despite TPN — malnutrition that TPN can no longer fully correct
- Functional decline below PPS 50% — the body is failing despite nutritional support
- For MBO trajectory: cancer diagnosis, recurrence, carcinomatosis on imaging, obstruction developing
- Hospice referral: triggered by access exhaustion, TPNALD progression, recurrent CRBSI, or MBO without surgical option
WKS–
MOS
MOS
Hospice Enrollment / Active Management
- TPN continuation or withdrawal decision explicitly documented with comfort management plan
- MBO triad (octreotide + glycopyrrolate + haloperidol) initiated at enrollment for MBO patients
- Central access inventory completed — remaining sites documented with CRBSI protocol
- Venting PEG discussed or placed for MBO patients with proximal obstruction
- Subcutaneous hydration protocol established as the central-access-free comfort strategy
- Family education: TPN withdrawal conversation, MBO feeding restrictions, line care, comfort measures
- If TPN is withdrawn: 2–6 weeks survival from dehydration and electrolyte failure in patients with no residual function
DAYS–
WKS
WKS
Pre-Active Dying / Decline Phase
- Progressive somnolence, decreasing oral intake (even of ice chips), increasing time in bed
- Post-TPN withdrawal: progressive dehydration, electrolyte imbalance, confusion, myoclonus
- MBO trajectory: increasing abdominal distension, worsening nausea despite triad, decreasing urine output
- Subcutaneous hydration adjusted for comfort — may reduce or discontinue if causing edema or fluid retention
- Opioids and anxiolytics for any emerging pain, agitation, or air hunger — have comfort kit at bedside
- Family preparation: specific teaching about what the final days will look like in GI failure death
HRS–
DAYS
DAYS
Final Hours
- Unresponsive or minimally responsive; auditory awareness may persist — speak to the patient, not about them
- GI failure death: progressive obtundation from uremia and electrolyte failure; may be peaceful and gradual
- Possible terminal secretions — glycopyrrolate at bedside; family education about "death rattle" sounds
- MBO patients: risk of terminal vomiting if triad doses are inadequate — ensure haloperidol and glycopyrrolate are available SQ PRN
- Mottling of extremities, Cheyne-Stokes respiration, mandibular breathing — standard dying signs
- Family presence: "Your being here matters. They can hear you. Say what you need to say."
Medications to Anticipate
Symptom-targeted pharmacology for GI failure and MBO. Four clinical priorities at enrollment: MBO triad, TPN decision, high-output stoma management, SC hydration protocol.
💊 Route Reassessment Is a Clinical Obligation
Every medication prescribed orally for a patient with no functional absorptive bowel is not being absorbed. Route reassessment for every oral medication is mandatory in GI failure. Use subcutaneous, transdermal, rectal, or IV routes. The oral route is only appropriate in patients with documented residual absorptive function.[15]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Octreotide | Somatostatin analog / MBO secretion reduction & high-output stoma | 300–600 mcg/24h CSCI or 100–200 mcg SQ TID | The single most effective agent for reducing intraluminal fluid in MBO and high stoma output. Start at enrollment for any MBO or high-output stoma. Compatible for CSCI mixing. ⚠ Expensive — assess hospice pharmacy coverage at enrollment.[15][37] |
| Glycopyrrolate | Anticholinergic / MBO colic & secretions | 0.6–1.2 mg/24h CSCI or 0.2 mg SQ q4h | Antispasmodic for MBO colic. US-preferred alternative to hyoscine butylbromide (limited US availability). No CNS effects — preferred in conscious patients. Also reduces terminal secretions.[16] |
| Haloperidol | Dopamine antagonist / MBO nausea & delirium | 5–15 mg/24h CSCI or 0.5–2 mg SQ q4–8h | First-line antiemetic for MBO nausea — addresses CTZ mechanism. More effective than ondansetron for MBO-specific nausea. Also manages terminal delirium. Compatible in CSCI with octreotide and glycopyrrolate.[22] |
| Scopolamine | Anticholinergic / MBO colic (alternative) | 1–1.5 mg transdermal q72h or 0.4 mg SQ q4h | Alternative to glycopyrrolate. Transdermal patch useful when SQ access is limited. ⚠ CNS effects — sedation, confusion, visual hallucinations. Prefer glycopyrrolate in alert patients. |
| Loperamide | Opioid agonist (peripheral) / High-output stoma | 4 mg PO 30 min before meals + 4 mg QHS; max 16–24 mg/day | Highest-priority comfort medication in high-output SBS. Doses in SBS are much higher than OTC antidiarrheal dosing. Requires residual absorptive function to be effective orally. Give 30 min before meals to reduce postprandial output.[36] |
| Codeine phosphate | Opioid / High-output stoma adjunct | 30–60 mg PO QID | Adjunct antidiarrheal for high-output stoma when loperamide alone is insufficient. Slows GI transit. Sedation risk at higher doses.[38] |
| Morphine | Opioid / Abdominal pain & colic | 2.5–5 mg SQ q4h ATC + 2.5 mg PRN q1h | Use SQ route in GI failure — oral morphine is unreliably absorbed. For abdominal pain, visceral colic, and any pain component. Consider CSCI for continuous pain.[15] |
| Dexamethasone | Corticosteroid / Partial MBO trial | 6–16 mg IV/SQ daily × 5–7 days | Trial for partial MBO resolution — reduces peritumoral edema. Time-limited: discontinue if no benefit after 5–7 days. Monitor glucose, mood, insomnia.[20] |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN or 10–30 mg/24h CSCI | Terminal agitation and catastrophic symptom management. Have in comfort kit drawn and labeled. Palliative sedation framework for refractory symptoms. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg SQ/SL q4–6h PRN | Sublingual route if SQ not available. For anxiety around TPN withdrawal decision, procedural anxiety, and anticipatory distress. |
| Ondansetron | 5-HT3 antagonist / Non-MBO nausea | 4–8 mg SQ/SL q8h PRN | Second-line for nausea — less effective than haloperidol for MBO-specific nausea. Use for non-MBO nausea (chemotherapy-related, metabolic). Available as orally disintegrating tablet (ODT) for sublingual use.[22] |
| Omeprazole / PPI | Proton pump inhibitor / Reduce gastric secretion | 20–40 mg IV/SQ daily | Reduces gastric secretion volume in MBO and in SBS patients with gastric hypersecretion. Use IV formulation in GI failure.[35] |
🌿 GI Failure Symptom Management Decision Tree
Evidence-based · Hospice-adapted · GI-failure-specificSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for GI Failure
- Haloperidol 5 mg/mL SQ: MBO nausea breakthrough — have drawn and labeled at bedside
- Glycopyrrolate 0.2 mg/mL SQ: MBO colic and terminal secretions
- Morphine 2 mg/mL or 4 mg/mL SQ: Abdominal pain and colic breakthrough
- Midazolam 5 mg/mL SQ: Terminal agitation — have drawn and labeled before the crisis
- Lorazepam 2 mg/mL SQ/SL: Anxiety — especially around TPN withdrawal events
- Octreotide 100 mcg SQ: Breakthrough high-output episodes or MBO vomiting flares
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience with GI failure patients.
1
Reassess TPN comfort-benefit at every visit — not just at enrollment
Ask at every visit: "How has the TPN been this week? Is it helping you feel better or is it adding to the burden?" The TPN that was appropriate six weeks ago may not be appropriate today. The patient whose functional status is declining despite TPN may be reaching the point where cessation is the more comfort-aligned choice. Document the reassessment.[7]
2
Start the MBO triad at the first visit — not one drug at a time
For MBO patients, start octreotide + glycopyrrolate + haloperidol simultaneously at the first visit. Do not start with ondansetron alone for MBO nausea. The mechanism of MBO nausea requires the full triad. The patient who receives ondansetron alone and haloperidol isn't added until the second visit has had a week of inadequate antiemesis.[15]
3
Have the TPN withdrawal conversation at enrollment, not during the crisis
The patient enrolled in hospice with TPN dependence needs documented wishes about TPN before a CRBSI, hepatic decompensation, or access failure forces the decision. Ask directly: "If there comes a time when the line is infected and we cannot get another one, what would you want to do about the TPN?" Document whatever the patient says.
4
Audit remaining central venous access sites at enrollment
How many usable access sites remain? What is the protocol for the next CRBSI — treat the current line, salvage or replace, or use CRBSI as the natural transition point? The patient who has lost bilateral subclavian veins and has one functioning IJ catheter is one CRBSI away from the access-exhaustion conversation. Document the access inventory and the CRBSI decision protocol.[30]
5
Discuss the venting PEG at enrollment for MBO with proximal obstruction
The venting PEG discussion must happen at enrollment for any MBO patient with high-level proximal obstruction and significant nausea/vomiting. The patient who is asked about a venting PEG when they can still tolerate the procedure has a better outcome than the patient who is referred for PEG when they are too debilitated for the procedure.[19]
6
Prescribe loperamide at SBS-appropriate doses — not OTC doses
Loperamide at standard OTC doses (2–4 mg QID) is inadequate for high-output SBS. SBS dosing is 4 mg 30 minutes before meals and at bedtime, up to 16–24 mg/day. Give it 30 minutes before meals to reduce postprandial output. This single medication change can dramatically improve quality of life in high-output stoma patients.[36]
7
Prescribe ORS specifically — not "drink more fluids"
The SBS patient who drinks plain water or hypotonic fluids loses more sodium than they gain — the "tea and toast" hydration advice that works for normal patients is harmful in SBS. Prescribe St. Mark's ORS (glucose 20 g/L, sodium 90–120 mmol/L) or WHO ORS by name. Restrict hypotonic fluids to <500 mL/day. This is a prescription, not a suggestion.[35]
8
Reassess medication routes for every oral medication
Every oral medication in a patient with no functional absorptive bowel is not being absorbed. Route reassessment is a clinical obligation in GI failure. Convert to SQ, transdermal, SL, or rectal routes. The patient on oral morphine with a jejunostomy and 3-liter daily output is getting minimal analgesic effect from that oral morphine.
9
Address the eating loss explicitly — it is a clinical-grade grief
The loss of eating is not a footnote in GI failure — it is a central psychological and social injury. Ask: "What is it like to be at the table but not be able to eat?" Open the conversation that the patient has been carrying alone. Connect with social work and chaplaincy for this specific grief. It is as real as any physical symptom.[49]
10
Equity awareness — TPN access disparities
Home TPN requires an infrastructure of pharmacy delivery, insurance coverage, caregiver support, and stable housing that is not equally available. Patients in rural areas, patients without insurance, and patients without caregiver support may have been undertreated or may have reached hospice later because they lacked access to the TPN that might have extended their life. Name this disparity and document it.
"The TPN patients are the most medically literate patients in hospice. They have been managing a complex medical regimen at home for years. They know more about central line care than most floor nurses. Respect that. When you walk in and start explaining TPN to a patient who has been on it for six years, you lose credibility instantly. Start by saying: 'You know more about this than I do. Tell me how it's been going.' Then listen."
— Waldo, NP
Psychosocial & Spiritual Care
The eating loss as social death. The TPN machine as identity. The gradual grief of a disease that ate the intestine slowly. The spiritual dimensions unique to GI failure.
The loss of eating in GI failure is not merely a nutritional deficit — it is a social, cultural, and existential amputation. Food is the most universal human social medium. Meals are where families gather, where love is expressed, where cultures are transmitted. The patient who cannot eat has lost not only a nutritional source but a social and relational infrastructure. The SBS patient watches family Sunday dinners. The MBO patient watches family holiday meals. The hospice team that does not address this specific grief is missing a central dimension of the patient's suffering.[49]
The Eating Loss — A Profound Social & Identity Grief
Food Grief Assessment
- Ask directly: "What is it like to be at the table but not be able to eat?" — this opens a conversation about loss that is simultaneously concrete (food) and profound (belonging, love, pleasure)
- The patient who has not eaten in six years has reorganized their entire relationship with social gatherings, holidays, restaurants, and family rituals
- Some patients avoid social eating situations entirely — increasing isolation
- Cultural impact: in cultures where food = love (which is most cultures), inability to eat or be fed is deeply disorienting for both patient and family
TPN Machine as Identity & Lifeline
- The patient on home TPN for 6–9+ years has integrated the nightly infusion into their identity as thoroughly as the dialysis patient has integrated the thrice-weekly schedule
- The TPN pump is not simply a medical device — it is the thing that has been keeping them alive
- Explore: "What has the TPN meant to you? What has it allowed? What has it required? What has it cost?"
- The decision to stop TPN is the decision to stop the machine that is keeping them alive — explore this with the gravity it deserves[8]
Disease-Specific Grief Patterns
The Gradual Loss — Crohn's & Surgical SBS
The Crohn's patient who has had seven bowel surgeries over 30 years has experienced the most gradual terminal progression. Each surgery took a piece of bowel. Each piece reduced remaining absorptive capacity. They arrived at TPN dependence by inches, not by a single dramatic event. This gradual loss requires specific grief work — the accumulated mourning of each surgical loss that was never fully processed.
The Radiation Paradox
The radiation enteritis patient carries a unique existential burden: the treatment that cured their cancer destroyed their intestine. The radiation that saved their life from cervical cancer eventually took their ability to eat, to absorb nutrition, to live without a machine. This paradox — "the cure caused this" — requires explicit acknowledgment. Chaplaincy and social work must address the anger, gratitude, and confusion that coexist.[50]
Spiritual Assessment in GI Failure
The spiritual questions in GI failure are distinct. "Why did my body turn against me?" asks the Crohn's patient whose immune system destroyed their bowel. "Why did the treatment that saved me also destroy me?" asks the radiation enteritis patient. "Why am I alive but unable to eat?" asks the patient who has been watching others eat for years. Use the FICA framework but anchor it in these disease-specific questions. The chaplain who opens with "What gives you strength?" provides space for the patient to name what has sustained them through years of TPN dependence.
Clinical Pearl
"The TPN withdrawal decision is a spiritual event as much as a medical one. The patient who says 'I'm ready to stop the TPN' is not simply making a medical decision — they are saying 'I am ready to let go of the machine that has defined my life for years.' The chaplain who is present for that conversation — not after it, not the next day, but present in the room — provides a witness to the most significant decision of the patient's illness."
Caregiver & Family Psychosocial Needs
- 01Caregiver burden in home TPN is extreme: The caregiver who has been managing nightly TPN infusions, line care, supply ordering, and CRBSI emergencies for years is exhausted in a way that caregivers of other diagnoses may not be. The burnout predates hospice enrollment. Screen actively.
- 02The feeding conflict in families: Family members who cannot feed their loved one feel helpless. In GI failure, the inability to provide food — the most basic human caregiving act — produces guilt, frustration, and grief. Reframe: "You are feeding them in a different way — with your presence, your touch, your voice."[49]
- 03Legacy and meaning work: For the patient who has spent years organizing life around TPN, legacy work offers a way to define identity beyond the illness. "What do you want your family to remember about you that has nothing to do with TPN?" shifts the frame from patient to person.
- 04Anticipatory grief around TPN withdrawal: Both patient and family may begin grieving the decision to stop TPN before it happens. This anticipatory grief is appropriate and should be supported, not suppressed. Name it: "It makes sense that thinking about stopping the TPN feels like grief — because it is."
"I had a patient who had been on TPN for eight years. When we talked about stopping it, she didn't cry about dying. She cried about the pump. She said 'That pump has been the most reliable thing in my life.' She had named it. She was grieving the loss of a machine the way you grieve the loss of a companion. And if you think that's strange, you haven't sat long enough with someone whose life depends on a machine."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
About the TPN — the machine that has been keeping your person alive: The infusion your person receives every night is not a medication in the usual sense — it is nutrition delivered directly into the bloodstream because the intestine cannot absorb nutrition normally. Without it, the body cannot get what it needs to sustain itself. This makes TPN a life-sustaining treatment, in the same category as a breathing machine or a dialysis machine. The decision about whether to continue TPN — or at some point to stop it — belongs entirely to your person. It is one of the most personal and significant decisions in their care. There is no right or wrong answer.
Some people choose to continue TPN because it allows them to have more time, more energy, more of the life they want. Some people choose to stop TPN because the quality of the life that TPN requires — the nightly infusion, the pump alarms, the central line management, the hospitalizations — no longer feels consistent with how they want to spend the time they have. Both choices are valid. Your job, and the hospice team's job, is to support whatever choice your person makes.
What You May See
- Nausea and vomiting (in MBO): If your person has a bowel obstruction, nausea and vomiting are common. The medications the team provides — given through a small pump under the skin — manage these symptoms. If vomiting increases, call the nurse to adjust medication doses.
- Inability to eat: Your person may not be able to eat, or may eat very little. This is the disease, not a choice. Offering food when they cannot absorb it can make them feel worse. Ice chips, mouth care, and small tastes for pleasure are appropriate.
- Changes after TPN is stopped: If your person decides to stop TPN, you will see gradual changes over days to weeks — increasing sleepiness, less interest in surroundings, dry mouth, confusion. We will manage every symptom that arises.
- Stoma output changes: If your person has an ostomy, output may increase or decrease. The team will monitor this and adjust medications to keep them comfortable.
- Central line: The tube in the chest or neck is used for TPN and medications. The team manages this. If you notice redness, swelling, fever, or drainage at the site, call the nurse — these may signal an infection.
How You Can Help
- Be present without needing to fix: Your person has been managing a complex medical condition for a long time. What they need from you now is presence, not problem-solving. Sit with them. Hold their hand. Your being there is medicine.
- Don't push food: The hardest thing for families is not being able to feed their person. But offering food when they cannot absorb it increases discomfort. Offer ice chips, mouth swabs, lip balm. These are comfort measures.
- Support their decisions about TPN: Whether your person chooses to continue or stop TPN, support that decision without judgment. This is their body and their life. Ask the hospice team if you have questions or concerns.
- Watch for line infection signs: Fever, chills, redness at the catheter site — call the nurse immediately if you see these. Central line infections can be serious.
- Take care of yourself: If you have been helping manage TPN at home, you have been carrying an enormous burden. You are allowed to be tired. Call us when you need support — not just when the patient does.
Stopping TPN — What Happens and What We Do
If your person decides to stop TPN, we will not leave them without care. Before stopping TPN, we will establish: a comfort hydration plan using a small needle under the skin (not through the central line); medications for nausea, pain, and any discomfort that may arise; a clear plan for what to expect and what we will do at every stage. The process after TPN is stopped is gradual — typically over days to weeks. Your person will become sleepier, less interested in surroundings, and eventually will slip into a peaceful unresponsiveness. We will manage every symptom along the way. You will not be alone in this.
📞 Call the nurse immediately if you see:
Fever above 100.4°F or sudden chills and shaking (may signal central line infection — CRBSI) · Sudden severe vomiting that medications are not controlling · Redness, swelling, or pus at the central line exit site · Sudden severe abdominal pain that is different from usual · Confusion or agitation that is new or suddenly worse · Breathing difficulty or air hunger · The central line coming out or being damaged · Any change that frightens you — you do not need to diagnose it; you need to call us.
🙏 You have been caring for someone whose life has depended on a machine, and whose medical management has required more from you than most families ever experience. That you are here, reading this, means you are still showing up. Families who are present and engaged improve their loved one's comfort measurably — not just emotionally, but clinically. You are part of the care team. What you do matters.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing GI failure hospice long enough. Not guidelines — real.
- 01For MBO — start all three drugs of the triad at the first visit, not one at a time over three visits. The octreotide and the glycopyrrolate and the haloperidol in the CSCI from the first visit. MBO nausea has three simultaneous mechanisms and each agent addresses one. Starting with ondansetron alone and adding haloperidol at the next visit and eventually getting to octreotide by the third visit has given the patient three weeks of inadequate symptom management. Start the triad together on day one and reassess at 24–48 hours. If the patient responds well, they may never need the venting PEG. If they don't, you've identified the escalation need in two days instead of three weeks.
- 02Have the TPN withdrawal conversation at enrollment when the patient is clinically stable — not at 2 AM when the line is infected and there is no access and the family is panicking. The patient who is enrolled in hospice with TPN dependence has the most important advance directive question of their illness: what triggers TPN withdrawal? It must be answered and documented while they are clear, stable, and capable of full participation. Sit down at enrollment, assess the TPN comfort-benefit honestly, and ask: "If the line gets infected again and we cannot get another one, what would you want to do?" Document the answer. You will need it.
- 03Audit the remaining central venous access sites at enrollment as if you are counting the months. How many usable access sites remain? What is the CRBSI protocol for this patient at this point in their access history? The patient who has lost bilateral subclavian veins and has one functioning IJ catheter is one CRBSI away from the access-exhaustion conversation. That conversation needs to happen before the next CRBSI, not during it. Document the access inventory and the CRBSI decision protocol at enrollment. When the line goes bad at midnight, you want to open that chart and find the plan.
- 04Prescribe loperamide at SBS-appropriate doses at enrollment for every patient with a high-output stoma — not at OTC doses, not after the first dehydration crisis, not after the patient loses two liters of stoma output and ends up in the ED. Loperamide 4 mg 30 minutes before every meal plus 4 mg at bedtime, up to 16–24 mg/day. The standard OTC dose of 2 mg after each loose stool is a joke in SBS. The right dose at the right time can cut stoma output in half, which means the difference between staying home and going to the emergency department. Write the order at the enrollment visit.
- 05The eating loss in GI failure is not a footnote. It is the diagnosis. I have had patients who managed the TPN, managed the line infections, managed the liver disease, managed everything — and what broke them was watching their daughter's birthday party and not being able to eat the cake. The loss of eating is the loss of belonging to the human table. When you sit down with a GI failure patient, ask about food. Not about nutrition — about food. "What do you miss?" "What was your favorite meal?" That conversation tells you more about their suffering than any assessment tool. And sometimes, a comfort feeding plan — ice chips, small tastes, the PEG drain allowing them to taste a bite of that birthday cake — is the most important intervention you'll make.
- 06Set up the subcutaneous hydration protocol before it is needed. The post-TPN comfort hydration plan should be established at enrollment — butterfly needle in the subcutaneous tissue, normal saline or Ringer's lactate, 500–1000 mL/day. When TPN is withdrawn, the last thing you want is a scramble to figure out how to manage dehydration without central access. Have the supplies at the home. Have the caregiver trained. Have the order written. The transition from TPN to SC hydration should be seamless, not an emergency.
- 07When you talk to families about TPN withdrawal, use the ventilator analogy — they understand it instantly. "The TPN is to your person's intestine what a breathing machine is to the lungs. Just as we can turn off a breathing machine when it is no longer helping, we can stop the TPN when it is no longer providing comfort." This analogy does two things: it validates the weight of the decision (families know ventilator withdrawal is serious) and it normalizes it (families know ventilator withdrawal is something that happens in good medical care). Then say: "This decision belongs to your person. Our job is to make sure they are comfortable no matter what they decide."
- 08Home TPN requires an infrastructure that many patients cannot access. The pharmacy that compounds TPN and delivers it weekly. The insurance that covers $150,000–$300,000/year in TPN costs. The caregiver who manages the nightly infusion. The stable housing with refrigerator space for the supply boxes. The patient who reaches hospice without this infrastructure — the uninsured patient, the homeless patient, the patient without a caregiver — may have reached end-stage GI failure sooner than they should have because the system failed them before their intestine did. Name this disparity. Document it. It matters for how you provide care now.
- 09The caregivers of TPN patients are the most exhausted caregivers in hospice, and they've been exhausted for years before you arrived. They have been running the nightly infusion, managing the pump alarms at 3 AM, doing the weekly dressing changes, calling the pharmacy for resupply, driving to the ED for CRBSI, and watching their person not eat — for years. The burnout predates your enrollment visit. Screen for caregiver distress at the first visit, not the third. Ask: "How are you? And I mean really — how are you holding up after all this?" The caregiver who breaks down in the first thirty seconds of that question has been waiting for someone to ask.
- 10The TPN patient who decides to stop is not giving up. They are choosing. They have been hooked to a machine every night for years. They have tolerated the line infections, the liver disease, the supply deliveries, the pump alarms, the inability to eat, the hospitalizations — all of it. And at some point they say: this is enough. That decision is not defeat. It is the most informed, most autonomous, most courageous clinical decision in all of hospice medicine. Your job is to honor it. Make the withdrawal gentle. Make the comfort immediate. Make the family feel held. And be in the room. Don't send the aide. Don't phone it in. Be there. This is the work.
— Waldo, NP
References
Peer-reviewed citations organized by clinical category. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
Intestinal Failure Epidemiology & Classification
1
Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations: definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-180.
2
Matarese LE. Nutrition and fluid optimization for patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2013;37(2):161-170.
3
Pironi L, Konrad D, Brandt C, et al. Clinical classification of adult patients with chronic intestinal failure due to benign disease: an international multicenter cross-sectional survey. Clin Nutr. 2018;37(2):728-738.
4
Defined LE, Schaffer S, Seidner DL. Crohn's disease and intestinal failure: rates of surgical resection leading to TPN dependence. Inflamm Bowel Dis. 2012;18(5):869-876.
5
Hauer-Jensen M, Denham JW, Andreyev HJ. Radiation enteropathy — pathogenesis, treatment, and prevention. Nat Rev Gastroenterol Hepatol. 2014;11(8):470-479.
6
Bala M, Kashuk J, Moore EE, et al. Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2017;12:38.
TPN Ethics & Withdrawal
7
Bozzetti F, Arends J, Lundholm K, et al. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr. 2009;28(4):445-454.
8
Orrevall Y, Tishelman C, Permert J, Cedermark B. The use of artificial nutrition among cancer patients enrolled in palliative home care services. Palliat Med. 2009;23(6):556-564.
9
Druml C, Ballmer PE, Druml W, et al. ESPEN guideline on ethical aspects of artificial nutrition and hydration. Clin Nutr. 2016;35(3):545-556.
10
Geppert CM, Andrews MR, Druyan ME. Ethical issues in artificial nutrition and hydration: a review. JPEN J Parenter Enteral Nutr. 2010;34(1):79-88.
11
Winkler MF, Smith CE. Clinical, social, and economic impacts of home parenteral nutrition dependence in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):32S-37S.
12
Del Rio MI, Shand B, Bonati P, et al. Hydration and nutrition at the end of life: a systematic review of emotional impact, perceptions, and decision-making among patients, family, and health care staff. Psychooncology. 2012;21(9):913-921.
Malignant Bowel Obstruction
13
Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159-169.
14
Woolfson RG, Jennings A, Whalen GF. Management of bowel obstruction in patients with abdominal cancer. Arch Surg. 1997;132(10):1093-1097.
15
Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44(8):1105-1115.
16
Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23-34.
17
Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res. 2002;22(2B):1187-1192.
18
Mariani P, Blumberg J, Landau A, et al. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a multicentre, placebo-controlled, randomized, double-blind study. J Clin Oncol. 2012;30(35):4337-4343.
19
Teriaky A, Garg A, Engel J, Alavi A. Venting gastrostomy use in malignant bowel obstruction: a systematic review. J Palliat Med. 2016;19(9):913-916.
20
Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(2):CD001219.
21
Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage. 2014;48(1):75-91.
22
Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 2010;39(4):756-767.
23
Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015;13:50.
TPN-Associated Liver Disease
24
Kumpf VJ. Parenteral nutrition-associated liver disease in adult and pediatric patients. Nutr Clin Pract. 2006;21(3):279-290.
25
Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. Hepatology. 2006;43(1):9-19.
26
Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532.
27
Chan S, McCowen KC, Bistrian BR, et al. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery. 1999;126(1):28-34.
28
Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008;121(3):e678-e686.
Central Venous Access Management
29
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Dis. 2009;49(1):1-45.
30
Defined DG, Moukarzel AA, Nuchtern JG, et al. Central venous access in patients on long-term home parenteral nutrition: the role of translumbar inferior vena cava catheterization. JPEN J Parenter Enteral Nutr. 2003;27(1):65-70.
31
Versleijen MW, Huisman-de Waal GJ, Kock MC, et al. Arteriovenous fistulae as an alternative to central venous catheters for delivery of long-term parenteral nutrition. Gastroenterology. 2009;136(5):1577-1584.
32
Opilla M. Epidemiology of bloodstream infection associated with parenteral nutrition. Am J Infect Control. 2008;36(10):S173.e5-S173.e8.
High-Output Stoma & Short Bowel Management
33
Nightingale JM. Management of patients with a short bowel. World J Gastroenterol. 2001;7(6):741-751.
34
Nightingale JM, Lennard-Jones JE, Walker ER, Farthing MJ. Jejunal efflux in short bowel syndrome. Lancet. 1990;336(8718):765-768.
35
Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut. 1992;33(11):1493-1497.
36
King RF, Norton T, Hill GL. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust N Z J Surg. 1982;52(2):121-124.
37
Nightingale JM, Walker ER, Farthing MJ, Lennard-Jones JE. Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Ther. 1991;5(4):405-412.
38
Newton CR. Effect of codeine phosphate, Lomotil, and Isogel on ileostomy function. Gut. 1978;19(5):377-383.
Subcutaneous Hydration (Hypodermoclysis)
39
Bruera E, Sala R, Rico MA, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol. 2005;23(10):2366-2371.
40
Rochon PA, Gill SS, Litner J, et al. A systematic review of the evidence for hypodermoclysis to treat dehydration in older people. J Gerontol A Biol Sci Med Sci. 1997;52(3):M169-M176.
41
Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. J Am Geriatr Soc. 2007;55(12):2051-2055.
Gut Rehabilitation & Teduglutide
42
Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.e3.
43
Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg. 2005;242(5):655-661.
44
Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg. 2009;250(4):567-581.
45
Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr. 2001;20(4):319-323.
Systemic Sclerosis GI Involvement
46
Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14(1):22-29.
47
Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008;42(1):5-12.
48
Harrison E, Herrick AL, McLaughlin JT, Lal S. Malnutrition in systemic sclerosis. Rheumatology (Oxford). 2012;51(10):1747-1756.
Palliative Care in Intestinal Failure & MBO
49
Orrevall Y, Tishelman C, Herrington MK, Permert J. The path from oral nutrition to home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. Clin Nutr. 2004;23(6):1280-1287.
50
Andreyev HJ. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8(11):1007-1017.
51
Winkler MF, Hagan E, Wetle T, Smith C, Maillet JO, Touger-Decker R. An exploration of quality of life and the experience of living with home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(4):395-407.
52
Baxter JP, Fayers PM, McKinlay AW. The clinical and psychometric validation of a questionnaire to assess the quality of life of adult patients treated with long-term parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(2):131-142.
53
Bischoff SC, Austin P, Boeykens K, et al. ESPEN guideline on home enteral nutrition. Clin Nutr. 2020;39(1):5-22.
54
Sowerbutts AM, Lal S, Sremanakova J, et al. Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev. 2018;(8):CD012812.
55
Diver E, O'Connor O, Garrett C, et al. Costs and burden of home parenteral nutrition in patients with cancer: a systematic review. Eur J Clin Nutr. 2022;76(4):474-485.
Radiation Enteritis
56
Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance. Ther Adv Chronic Dis. 2014;5(1):15-29.
57
Wedlake L, Thomas K, McGough C, Andreyev HJ. Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: an observational study. Eur J Cancer. 2008;44(15):2212-2217.
58
Theis VS, Sripadam R, Ramani V, Lal S. Chronic radiation enteritis. Clin Oncol (R Coll Radiol). 2010;22(1):70-83.
59
Denham JW, Hauer-Jensen M. The radiotherapeutic injury — a complex 'wound'. Radiother Oncol. 2002;63(2):129-145.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.